Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Type
Results
All (4)
All (4) ((4 results))
- Articles and reports: 82-003-X201500614196Description:
This study investigates the feasibility and validity of using personal health insurance numbers to deterministically link the CCR and the Discharge Abstract Database to obtain hospitalization information about people with primary cancers.
Release date: 2015-06-17 - Articles and reports: 82-003-X201500514169Description:
The Cancer Risk Management Model incorporates the risk of developing cancer, disease screening and clinical management with cost and labour data to assess health outcomes and economic impact. A screening module added to the lung cancer module enables a variety of scenarios to be evaluated for different target populations with varying rates of participation, compliance, and frequency of low-dose computed tomography screening.
Release date: 2015-05-20 - Surveys and statistical programs – Documentation: 11-522-X19990015658Description:
Radon, a naturally occurring gas found at some level in most homes, is an established risk factor for human lung cancer. The U.S. National Research Council (1999) has recently completed a comprehensive evaluation of the health risks of residential exposure to radon, and developed models for projecting radon lung cancer risks in the general population. This analysis suggests that radon may play a role in the etiology of 10-15% of all lung cancer cases in the United States, although these estimates are subject to considerable uncertainty. In this article, we present a partial analysis of uncertainty and variability in estimates of lung cancer risk due to residential exposure to radon in the United States using a general framework for the analysis of uncertainty and variability that we have developed previously. Specifically, we focus on estimates of the age-specific excess relative risk (ERR) and lifetime relative risk (LRR), both of which vary substantially among individuals.
Release date: 2000-03-02 - Articles and reports: 11F0019M1997099Geography: CanadaDescription:
Context : Lung cancer has been the leading cause of cancer deaths in Canadian males for many years, and since 1994, this has been the case for Canadian femalesas well. It is therefore important to evaluate the resources required for its diagnosis and treatment. This article presents an estimate of the direct medical costsassociated with the diagnosis and treatment of lung cancer calculated through the use of a micro-simulation model. For disease incidence, 1992 was chosen as thereference year, whereas costs are evaluated according to the rates that prevailed in 1993.Methods : A model for lung cancer has been incorporated into the Population Health Model (POHEM). The parameters of the model were drawn in part fromStatistics Canada's Canadian Cancer Registry (CCR), which provides information on the incidence and histological classification of lung cancer cases in Canada.The distribution of cancer stage at diagnosis was estimated by using information from two provincial cancer registries. A team of oncologists derived "typical" treatment approaches reflective of current practice, and the associated direct costs were calculated for these approaches. Once this information and the appropriatesurvival curves were incorporated into the POHEM model, overall costs of treatment were estimated by means of a Monte Carlo simulation.Results: It is estimated that overall, the direct medical costs of lung cancer diagnosis and treatment were just over $528 million. The cost per year of life gained as aresult of treatment of the disease was approximately $19,450. For the first time in Canada, it was possible to estimate the five year costs following diagnosis, bystage of the disease at the time of diagnosis. It was possible to estimate the cost per year of additional life gained for three alternative treatments of non small-cell lungcancer (NSCLC). Sensitivity analyses showed that these costs varied between $1,870 and $6,860 per year of additional life gained, which compares favourablywith the costs that the treatment of other diseases may involve.Conclusions: Contrary to widespread perceptions, it appears that the treatment of lung cancer is effective from an economic standpoint. In addition, the use of amicro-simulation model such as POHEM not only makes it possible to incorporate information from various sources in a coherent manner but also offers thepossibility of estimating the effect of alternative medical procedures from the standpoint of financial pressures on the health care system.
Release date: 1997-04-22
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (3)
Analysis (3) ((3 results))
- Articles and reports: 82-003-X201500614196Description:
This study investigates the feasibility and validity of using personal health insurance numbers to deterministically link the CCR and the Discharge Abstract Database to obtain hospitalization information about people with primary cancers.
Release date: 2015-06-17 - Articles and reports: 82-003-X201500514169Description:
The Cancer Risk Management Model incorporates the risk of developing cancer, disease screening and clinical management with cost and labour data to assess health outcomes and economic impact. A screening module added to the lung cancer module enables a variety of scenarios to be evaluated for different target populations with varying rates of participation, compliance, and frequency of low-dose computed tomography screening.
Release date: 2015-05-20 - Articles and reports: 11F0019M1997099Geography: CanadaDescription:
Context : Lung cancer has been the leading cause of cancer deaths in Canadian males for many years, and since 1994, this has been the case for Canadian femalesas well. It is therefore important to evaluate the resources required for its diagnosis and treatment. This article presents an estimate of the direct medical costsassociated with the diagnosis and treatment of lung cancer calculated through the use of a micro-simulation model. For disease incidence, 1992 was chosen as thereference year, whereas costs are evaluated according to the rates that prevailed in 1993.Methods : A model for lung cancer has been incorporated into the Population Health Model (POHEM). The parameters of the model were drawn in part fromStatistics Canada's Canadian Cancer Registry (CCR), which provides information on the incidence and histological classification of lung cancer cases in Canada.The distribution of cancer stage at diagnosis was estimated by using information from two provincial cancer registries. A team of oncologists derived "typical" treatment approaches reflective of current practice, and the associated direct costs were calculated for these approaches. Once this information and the appropriatesurvival curves were incorporated into the POHEM model, overall costs of treatment were estimated by means of a Monte Carlo simulation.Results: It is estimated that overall, the direct medical costs of lung cancer diagnosis and treatment were just over $528 million. The cost per year of life gained as aresult of treatment of the disease was approximately $19,450. For the first time in Canada, it was possible to estimate the five year costs following diagnosis, bystage of the disease at the time of diagnosis. It was possible to estimate the cost per year of additional life gained for three alternative treatments of non small-cell lungcancer (NSCLC). Sensitivity analyses showed that these costs varied between $1,870 and $6,860 per year of additional life gained, which compares favourablywith the costs that the treatment of other diseases may involve.Conclusions: Contrary to widespread perceptions, it appears that the treatment of lung cancer is effective from an economic standpoint. In addition, the use of amicro-simulation model such as POHEM not only makes it possible to incorporate information from various sources in a coherent manner but also offers thepossibility of estimating the effect of alternative medical procedures from the standpoint of financial pressures on the health care system.
Release date: 1997-04-22
Reference (1)
Reference (1) ((1 result))
- Surveys and statistical programs – Documentation: 11-522-X19990015658Description:
Radon, a naturally occurring gas found at some level in most homes, is an established risk factor for human lung cancer. The U.S. National Research Council (1999) has recently completed a comprehensive evaluation of the health risks of residential exposure to radon, and developed models for projecting radon lung cancer risks in the general population. This analysis suggests that radon may play a role in the etiology of 10-15% of all lung cancer cases in the United States, although these estimates are subject to considerable uncertainty. In this article, we present a partial analysis of uncertainty and variability in estimates of lung cancer risk due to residential exposure to radon in the United States using a general framework for the analysis of uncertainty and variability that we have developed previously. Specifically, we focus on estimates of the age-specific excess relative risk (ERR) and lifetime relative risk (LRR), both of which vary substantially among individuals.
Release date: 2000-03-02
- Date modified: